Company Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.
The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 254 |
| CEO | Grant Pickering |
Contact Details
Address: 825 Industrial Road, Suite 300 San Carlos, California 94070 United States | |
| Phone | 650 837 0111 |
| Website | vaxcyte.com |
Stock Details
| Ticker Symbol | PCVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001649094 |
| CUSIP Number | 92243G108 |
| ISIN Number | US92243G1085 |
| Employer ID | 46-4233385 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer and Director |
| Andrew L. Guggenhime M.B.A. | President and Chief Financial Officer |
| James Wassil M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Mikhail Eydelman J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Ashish Khanna M.B.A., Ph.D. | Co-Founder |
| Dr. Jeff Fairman Ph.D. | Co-Founder and Vice President of Research |
| Elvia Cowan | Senior Vice President of Finance and Principal Accounting Officer |
| Janet Graesser | Senior Vice President of Corporate Communications and Investor Relations |
| Whitney Jones | Chief People Officer |
| Paul W. Sauer M.B.A. | Senior Vice President of Process Development and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 144 | Filing |
| Nov 5, 2024 | 144 | Filing |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 1, 2024 | 144 | Filing |